Cryoport Inc (CYRX) - Total Liabilities
Based on the latest financial reports, Cryoport Inc (CYRX) has total liabilities worth $268.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cryoport Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how Cryoport Inc's total liabilities have evolved over time, based on quarterly financial data. See CYRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Cryoport Inc Competitors by Total Liabilities
The table below lists competitors of Cryoport Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mobilicom Limited Warrants
NASDAQ:MOBBW
|
USA | $11.91 Million |
|
CECEP Guozhen Environmental Protection Technology Co Ltd
SHE:300388
|
China | CN¥12.25 Billion |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥420.46 Million |
|
GCM Grosvenor Inc
NASDAQ:GCMG
|
USA | $566.50 Million |
|
SunCoke Energy Inc
NYSE:SXC
|
USA | $1.21 Billion |
|
Jiangsu Rainbow Heavy Industries Co Ltd
SHE:002483
|
China | CN¥7.53 Billion |
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
China | CN¥579.91 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Cryoport Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Cryoport Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cryoport Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cryoport Inc (2004–2025)
The table below shows the annual total liabilities of Cryoport Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $262.35 Million | -13.01% |
| 2024-12-31 | $301.59 Million | -35.66% |
| 2023-12-31 | $468.72 Million | -2.94% |
| 2022-12-31 | $482.91 Million | +2.50% |
| 2021-12-31 | $471.14 Million | +177.62% |
| 2020-12-31 | $169.71 Million | +1669.26% |
| 2019-12-31 | $9.59 Million | -46.93% |
| 2018-12-31 | $18.07 Million | +660.24% |
| 2017-12-31 | $2.38 Million | -2.23% |
| 2016-12-31 | $2.43 Million | -1.49% |
| 2015-12-31 | $2.47 Million | -18.35% |
| 2014-12-31 | $3.02 Million | -24.70% |
| 2013-12-31 | $4.01 Million | +5.12% |
| 2012-12-31 | $3.82 Million | +53.74% |
| 2011-12-31 | $2.48 Million | -51.13% |
| 2010-12-31 | $5.08 Million | -10.68% |
| 2009-12-31 | $5.69 Million | -3.50% |
| 2008-12-31 | $5.90 Million | +112.79% |
| 2007-12-31 | $2.77 Million | +18.25% |
| 2006-12-31 | $2.34 Million | -4.08% |
| 2005-12-31 | $2.44 Million | +8.10% |
| 2004-12-31 | $2.26 Million | -- |
About Cryoport Inc
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic … Read more